Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: Suppression of CYLD gene by LEF1

Leukemia

Volumn 26, Issue 6, 2012, Pages 1293-1300

  Liu, P ^a   Xu, B ^a   Shen, W ^a   Zhu, H ^a   Wu, W ^a   Fu, Y ^a   Chen, H ^a   Dong, H ^a   Zhu, Y ^a   Miao, K ^a   Xu, W ^a   Li, J ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

chronic lymphocytic leukemia; CYLD; LEF1; necroptosis

Indexed keywords

BENZYLOXYCARBONYLVALYLALALYLASPARTATE FLUOROMETHYLKETONE; CASPASE INHIBITOR; LYMPHOID ENHANCER FACTOR 1; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYLINDROMATOSIS GENE; GENE; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; MITOCHONDRION; NECROPTOSIS; PRIORITY JOURNAL; RIP3 GENE; TREATMENT RESPONSE; UPREGULATION;

BETA CATENIN; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LUCIFERASES; LYMPHOID ENHANCER-BINDING FACTOR 1; MITOCHONDRIA; NECROSIS; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS; WNT SIGNALING PATHWAY;

EID: 84862006553     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.357     Document Type: Article

References (40)

1. Zenz T, Mertens D, Kü ppers R, Dö hner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
3. Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Dö hner H et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res 2009; 69: 8977-8986.
4. Danilov AV, Danilova OV, Klein AK, Huber BT. Molecular pathogenesis of chronic lymphocytic leukemia. Curr Mol Med 2006; 6: 665-675. (Pubitemid 44377765)
5. Kolb JP, Kern C, Quiney C, Roman V, Billard C. Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord 2003; 3: 261-286. (Pubitemid 37540859)
6. Declercq W, Vanden Berghe T, Vandenabeele P. RIP kinases at the crossroads of cell death and survival. Cell 2009; 138: 229-232.
7. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008; 135: 1311-1323.
8. He S, Wang L, Miao L, Wang T, Du F, Zhao L et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009; 137: 1100-1111.
9. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009; 325: 332-336.
10. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-119.
11. Hovanes K, Li TW, Waterman ML. The human LEF-1 gene contains a promoter preferentially active in lymphocytes and encodes multiple isoforms derived from alternative splicing. Nucleic Acids Res 2000; 28: 1994-2003. (Pubitemid 30229667)
12. Kim YS, Morgan MJ, Choksi S, Liu ZG. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell 2007; 26: 675-687. (Pubitemid 46856240)
13. Lin Y, Choksi S, Shen HM, Yang QF, Hur GM, Kim YS et al. Tumor necrosis factorinduced nonapoptotic cell death requires receptor-interacting proteinmediated cellular reactive oxygen species accumulation. J Biol Chem 2004; 279: 10822-10828. (Pubitemid 38372695)
14. Gutié rrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Fermiñ án E et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenströ m's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007; 21: 541-549.
15. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26.
16. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-480.
17. Gutierrez Jr A, Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, Huddleston III PM et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood 2010; 116: 2975-2983.
18. Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, Schlö sser A et al. Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia 2010; 12: 326-335.
19. Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell 2008; 135: 1161-1163.
20. Schü tze S, Tchikov V, Schneider-Brachert W. Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat Rev Mol Cell Biol 2008; 9: 655-662. (Pubitemid 352032925)
21. Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 2009; 10: 348-355.
22. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 2008; 105: 11778-11783.
23. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 2008; 283: 24295-24299.
24. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703. (Pubitemid 351636305)
25. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 2010; 17: 25-34.
26. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000; 25: 160-165. (Pubitemid 30394985)
27. Simonson SJ, Wu ZH, Miyamoto S. CYLD: a DUB with many talents. Dev Cell 2007; 13: 601-603. (Pubitemid 350011993)
28. Wright A, Reiley WW, Chang M, Jin W, Lee AJ, Zhang M et al. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev Cell 2007; 13: 705-716. (Pubitemid 350011985)
29. Van de Wetering M, de Lau W, Clevers H. WNT signaling and lymphocyte development. Cell 2002; 109(Suppl): S13-S19. (Pubitemid 34457848)
30. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-850. (Pubitemid 40558990)
31. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 3118-3123. (Pubitemid 38327744)
32. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639-1647. (Pubitemid 33126814)
33. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K et al. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One 2009; 4: e8294.
34. Rivat C, Le Floch N, Sabbah M, Teyrol I, Redeuilh G, Bruyneel E et al. Synergistic cooperation between the AP-1 and LEF-1 transcription factors in activation of the matrilysin promoter by the src oncogene: implications in cellular invasion. FASEB J 2003; 17: 1721-1723.
35. Luderer HF, Gori F, Demay MB. Lymphoid enhancer-binding factor-1 (LEF1) interacts with the DNA-binding domain of the vitamin D receptor. J Biol Chem 2011; 286: 18444-18451.
36. Tandon B, Peterson L, Gao J, Nelson B, Ma S, Rosen S et al. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. Mod Pathol 24: 1433-1443.
37. Mendel DB, Hansen LP, Graves MK, Conley PB, Crabtree GR. HNF-1 alpha and HNF-1. beta (vHNF-1) share dimerization and homeo domains, but not activation domains, and form heterodimers in vitro. Genes Dev 1991; 5: 1042-1056. (Pubitemid 21906017)
38. Tutter AV, Fryer CJ, Jones KA. Chromatin-specific regulation of LEF-1-beta-catenin transcription activation and inhibition in vitro. Genes Dev 2001; 15: 3342-3354. (Pubitemid 34008198)
39. Sasaki T, Suzuki H, Yagi K, Furuhashi M, Yao R, Susa S et al. Lymphoid enhancer factor 1 makes cells resistant to transforming growth factor beta-induced repression of c-myc. Cancer Res 2003; 63: 801-806. (Pubitemid 36231979)
40. Eichhoff OM, Weeraratna A, Zipser MC, Denat L, Widmer DS, Xu M et al. Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res 2011; 24: 631-642.